Prothena Corporation PLC banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Ireland IE
Employees
67
IPO date
Dec 21, 2012

Prothena Corporation PLC is a biotechnology company that focuses on diseases caused by harmful proteins, especially neurodegenerative disorders and certain rare amyloid-related conditions. It does not sell a broad line of commercial medicines; instead, it develops drug candidates intended to stop or slow the protein misfolding and buildup that drives these illnesses.

Its main customers are not end patients in the usual retail sense. Prothena mainly works with large pharmaceutical partners, research collaborators, hospitals, and eventually physicians and health systems if its medicines reach the market. The company makes money through collaboration payments, licensing deals, research funding, and, if its programs succeed, future product sales or royalties.

What makes Prothena different is its narrow focus on difficult diseases where abnormal proteins are central to the problem. That puts it in a specialized role in the drug-development chain: it takes scientific ideas from early research into clinical testing, often with partners that help fund development and may later handle large-scale commercialization.

Prothena Corporation PLC Investor Relations

Address
77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands
Dublin
Ireland

Business Segments

Drug development

Prothena develops antibody-based medicines for diseases caused by misfolded proteins, with a focus on neurologic, amyloid, and immune-related conditions. It runs research, clinical testing, and partner programs for these...

Customers and revenue model

Management

Dr. Gene G. Kinney Ph.D.

President, CEO & Director

Biography unavailable

Mr. Tran B. Nguyen M.B.A.

CFO & Chief Strategy Officer

Biography unavailable

Mr. Brandon S. Smith

Chief Operating Officer

Biography unavailable

Ms. Carol D. Karp

Chief Regulatory Officer

Biography unavailable

Ms. Karin L. Walker CPA

Chief Accounting Officer & Controller

Biography unavailable

Dr. Wagner M. Zago Ph.D.

Chief Scientific Officer

Biography unavailable

Mr. Mark C. Johnson C.F.A.

Vice President of Investor Relations

Biography unavailable

Mr. Michael J. Malecek

Chief Legal Officer

Biography unavailable

Mr. David A. Ford

Chief People Officer

Biography unavailable

Dr. Chad J. Swanson Ph.D.

Chief Development Officer

Biography unavailable

1 / 10